Mehul Desai

List of Publications by Year
in descending order

21 papers	8,889 citations	331259 21 h-index	713013 21 g-index
21 all docs	21 docs citations	21 times ranked	8476 citing authors

#	Article	IF	Citations
1	Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 644-657.	13.9	5,629
2	Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events. Circulation, 2018, 137, 323-334.	1.6	393
3	Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus. Circulation, 2018, 138, 458-468.	1.6	370
4	Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 157-166.	1.8	356
5	Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)â€"A randomized placebo-controlled trial. American Heart Journal, 2013, 166, 217-223.e11.	1.2	290
6	Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. Journal of the American Society of Nephrology: JASN, 2017, 28, 368-375.	3.0	280
7	Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care, 2015, 38, 1680-1686.	4.3	278
8	Efficacy and Safety of Canagliflozin, an Inhibitor of Sodiumâ€"Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes. Diabetes Care, 2015, 38, 403-411.	4.3	196
9	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. American Journal of Nephrology, 2017, 46, 462-472.	1.4	194
10	Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2ÂDiabetes. Journal of the American College of Cardiology, 2017, 70, 704-712.	1.2	142
11	Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Studyâ€"Renal (<scp>CANVASâ€R</scp>): A randomized, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2017, 19, 387-393.	2.2	139
12	Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodiumâ€glucose coâ€transporterâ€2 inhibitors in the USA: A retrospective cohort study. Diabetes, Obesity and Metabolism, 2018, 20, 582-589.	2.2	108
13	Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. Diabetologia, 2019, 62, 926-938.	2.9	94
14	Optimizing the analysis strategy for the <scp>CANVAS</scp> Program: A prespecified plan for the integrated analyses of the <scp>CANVAS</scp> and <scp>CANVASâ€R</scp> trials. Diabetes, Obesity and Metabolism, 2017, 19, 926-935.	2.2	89
15	Canagliflozin: a sodium glucose coâ€transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Annals of the New York Academy of Sciences, 2015, 1358, 28-43.	1.8	75
16	Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. Diabetologia, 2019, 62, 1854-1867.	2.9	58
17	The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. Current Medical Research and Opinion, 2016, 32, 1375-1385.	0.9	55
18	Canagliflozin and Stroke in Type 2 Diabetes Mellitus. Stroke, 2019, 50, 396-404.	1.0	51

#	Article	IF	Citations
19	Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. Diabetes Therapy, 2015, 6, 289-302.	1.2	36
20	Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Current Medical Research and Opinion, 2017, 33, 553-562.	0.9	30
21	Renal safety of canagliflozin, a sodium glucose coâ€transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2017, 19, 897-900.	2.2	26